UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/587,372	06/12/2008	Miren Edurne Baroja Fernandez	U 016405-8	1684
140 LADAS & PAF	7590 10/28/201 RRY LLP	EXAMINER		
26 WEST 61ST STREET			PAGE, BRENT T	
NEW YORK, NY 10023			ART UNIT	PAPER NUMBER
			1638	
			NOTIFICATION DATE	DELIVERY MODE
			10/28/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

nyuspatactions@ladas.com

	Application No.	Applicant(s)			
	10/587,372	BAROJA FERNANDEZ ET AL.			
Office Action Summary	Examiner	Art Unit			
	BRENT PAGE	1638			
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING ID. - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by stature Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION .136(a). In no event, however, may a reply be tin d will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on <u>26</u> .	July 2006				
· · · · · · · · · · · · · · · · · · ·	is action is non-final.				
<u></u>	<i>,</i> —				
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) <u>1-43</u> is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-43</u> are subject to restriction and/or	awn from consideration.				
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) ☑ Notice of References Cited (PTO-892)	4) 🔲 Interview Summary				
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-10, 21-22, and 25-26, drawn to a first method of efficient production of high levels of recombinant sucrose synthase wherein the sucrose synthase is represented by SEQ ID NO:3, a first product, the enzyme product, and a first method of using in the production of UDPG.

Group II, claims 11-20, 23-24 and 27-28, drawn to a second method of efficient production of high levels of recombinant sucrose synthase wherein the sucrose synthase is represented by SEQ ID NO:11, a second product, the enzyme product, and a second method of using in the production of UDPG.

Group III, claims 29-33, drawn to a third method of using an enzyme product in the manufacture of assay kits.

Group IV, claims 34-43, drawn to a fourth method for the production of transgenic plants and a third product, the transgenic plants.

The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The Inventions I-IV are linked by the technical feature of recombinant sucrose synthase enzymes. It is noted since different SEQ ID NOs are claimed, that no one specific sucrose synthase may be the technical feature, but rather sucrose synthase in general. However, this feature is not special because it does not constitute an

advancement over the prior art. Zrenner et al (1995 The Plant Journal 7:97-107), in elucidating the role of sucrose synthase, transformed potato plants with recombinant DNA constructs that encode sucrose synthase.

Furthermore, the Inventions listed as I-IV are independent and distinct for the following reasons:

Invention I requires SEQ ID NO:3, not required by any other Invention and does not require the primer pairs or SEQ ID NO:11 of Invention II, the assay kit making material of Invention III, or the transgenic plant materials and method steps of Invention IV.

Invention II requires SEQ ID NO:11, not required by any other Invention and does not require the primer pairs or SEQ ID NO:3 of Invention I, the assay kit making material of Invention III, or the transgenic plant materials and method steps of Invention IV.

Invention III requires assay kit making materials not required by any other

Invention and does not require SEQ ID NO:3 required by Invention I, SEQ ID NO:11

required by Invention II or the transgenic plant materials and method steps of Invention IV.

Invention IV requires transgenic plant materials and method steps not required by any other Invention and does not require SEQ ID NO:3 required by Invention I, SEQ ID NO:11 required by Invention II or the assay kit making materials of Invention III.

The above listed Inventions lack unity, and also are independent and distinct from one another as discussed above and restriction is therefore proper.

Application/Control Number: 10/587,372

Art Unit: 1638

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Page 4

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENT PAGE whose telephone number is (571)272-5914. The examiner can normally be reached on Monday-Friday 8-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on (571)-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Brent Page/ Examiner, Art Unit 1638